



http://cdjournal.muk.ac.ir,    06 July 
   Chron Dis J, Vol. 9, No. 3, Summer 2021    103 
DOI: 10.22122/cdj.v9i3.630 Published by Vesnu Publications 
Association between the Ssp1 loci of intron II beta globin gene  








1 Department of Biology, Kurdistan Science and Research Branch, Islamic Azad University, Sanandaj, Iran 




BACKGROUND: Thalassemia is a common hereditary disorder of hemoglobin synthesis. In this study, the 
polymorphism of the site of Ssp1 intron II of β-globin gene was investigated in patients with thalassemia minor who 
referred to laboratory centers in Sanandaj and Marivan townships in Iran. 
METHODS: This was an analytical cross-sectional study. Initially, the questionnaires were completed to obtain the data. 
Based on complete blood count (CBC) and hemoglobin electrophoresis, carriers were diagnosed. Deoxyribonucleic acid 
(DNA) extraction was performed by the salting out method from all blood samples. The polymorphism of the Ssp1 loci of 
intron II beta globin gene was evaluated using the polymerase chain reaction-restriction fragment length polymorphism 
(PCR-RFLP) method with the effect of Ssp1 restriction enzyme on all DNA samples. 
RESULTS: The results showed that of the 200 individuals or 400 chromosomes examined, 166 individuals (78 and 
88% in cases and controls, respectively) were positive for SspI position and 34 individuals (22 and 12% in cases 
and controls, respectively) were negative. Additionally, statistical analysis suggested no significant relationship 
between these two groups in SspI position (OR = 0.483, P = 0.189). 
CONCLUSION: The polymorphism of SspI locus in this case study is informative of Kurdish population. 
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Introduction1 
Thalassemia is one of the most common 
genetic diseases in the world that is inherited 
as autosomal recessive. The disease is common 
in the Mediterranean, Middle East, and  
South-East Asian countries.1 1.5% of the 
world's population (80-90 million) are carriers 
of β-thalassemia, and more than 56,000 births 
per year lead to babies with thalassemia major 
worldwide, most of whom being in developing 
and poor countries.2 Beta-thalassemia has a 
high prevalence in Iran and the national 
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program for preventing β-thalassemia major 
has been in place since 1997. In this program, 
couples are screened for pathogenic mutations 
of beta-globin gene before marriage, and  
if both persons are carriers, pre-marital and 
pre-pregnancy counseling are performed.3-8 
The highest prevalence of beta-thalassemia 
carriers in Iran is 10% in north of the country, 
border of the Caspian Sea, and south of the 
Gulf region and the Oman Sea. This rate in 
other parts of the country is estimated as  
4%-8%.4 More than 95% of all β-thalassemia 
mutations are spot mutations in the β-globin 
gene and the rest of the type of other 
mutations. The studies carried out in the last 
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country indicate the dispersion of mutations in 
terms of type and frequency, due to  
genetic-ethnic heterogeneity.4-7 The IVSI-5 
mutation is the most common mutation in 
south east provinces including Sistan and 
Baluchistan and Kerman, however the 
mutation is less frequent in other parts of Iran. 
The mutations of IVSI-110, IVSI-1, Fr8-9, and 
C36-37 in Khuzestan, IVSII-1 in Mazandaran, 
and IVSII-1, C36-37, and IVSI-5 in Isfahan have 
the highest frequency.1-10  
In previous reports from western and 
northwestern provinces of Iran, the most 
frequent mutations are IVSII-1, Fr8-9, IVSI-1, 
IVSI-110, and C36-37.9,10 More than 200 
different mutations known for beta gene have 
been reported in over 60 Iranian patients. 
Considering that Iran has a high population 
with a combination of different ethnic groups, 
determining the frequency and distribution of 
mutations in different parts of the country 
seems necessary.4 However, due to the 
diversity of the population, immigration, and 
the domination of different ethnic groups 
throughout history, many mutations has not 
been reported. More than 40 different 
mutations in the β-globin gene have been 
reported in Iranian populations, but in some 
regions of Iran, mutation remains unknown in 
10-20% of thalassemia minor cases.11  
Regarding the location of the restriction 
enzymes in the exon and intron regions of the 
beta-globin gene, in addition to detecting 
mutations by direct sequencing, restriction 
enzymes and polymerase chain reaction-
restriction fragment length polymorphism 
(PCR-RFLP) techniques are also used to 
identify carriers of thalassemia. The locations 
of RFLP have been identified around the beta-
globin gene, most of which do not have known 
polymorphism in the population of different 
regions of Iran. Early studies carried out in the 
Mediterranean and African populations show 
that a polymorphic position in nucleotide 666 
in intron II of the β-globin gene is identifiable 
by the SspI restriction enzyme. Akhavan  
Niaki et al. investigated the frequency of 
polymorphisms of SspI loci in intron II in β-
globin gene in Mazandaran population.12 Their 
results showed that of the 422 chromosomes 
examined, 20.6% were negative for SspI. 
Negative positions were approximately equal 
to that of healthy and mutated chromosomes.12  
This loci (Avall in intron II of beta-globin 
gene) has been reported with a significant 
polymorphism in the β-globin gene in Iranian 
population.13 Consequently, in the present 
study, association between the Ssp1 loci of 
intron II beta globin gene with Beta 
Thalassemia-trait was investigated in 100 
individuals with minor thalassemia and 100 
healthy controls in Kurdistan population. 
Methods 
Sampling: In this analytical cross-sectional 
study, 100 patients with thalassemia minor 
were selected from Sanandaj, Marivan, and 
Saqez laboratories. The blood indexes of all 
specimens were measured by the automatic 
system (SYSMEX XS800I, Japan). From all 
subjects, hemoglobin electrophoresis was 
performed using alkaline PH acetate cellulose 
gel. In all patients, mean corpuscular volume 
(MCV) and mean corpuscular hemoglobin 
(MCH) were less than 82 fl and 25 pg, 
respectively, and hemoglobinA2 (HbA2) was  
> 3.5%. In addition, 100 subjects with the same 
age and spatial distribution as well as MCV 
more than 82 fl, MCH more than 25, and 
hemoglobin A2 > 3.5% were selected as 
healthy controls. The individuals who were 
willing to participate in the study were 
selected after completing the consent form and 
observing the ethics of medical research plans. 
5 cc of venous blood was taken from each 
subject and inserted in tubes containing 
ethylenediaminetetraacetic acid (EDTA) and 
kept at a temperature of 20 °C. 
Molecular Experiments 
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DNA of the blood samples was extracted by 
the salting out method according to the 
corresponding protocols. Therefore, 5 ml of the 
blood sample of each patient was poured into 
the test tubes containing 5 mg/l of EDTA and 
slowly blended. Then, 5 ml of cold-buffered 
lysis [white blood cell (WBC) lysis] containing 
tris, EDTA, and NaCl was added to each 
sample at various concentrations. The blended 
samples were centrifuged at 3000 rpm for 10 
minutes. After completion, the centrifugation 
of the supernatant was discarded and added to 
the clot residual of 5 ml of phosphate buffered 
saline (PBS) and again centrifuged at about 
3000 rpm for 10 minutes. These steps 
continued until the white mass was completely 
white. After completion, the last step of the 
supernatant was discarded and added to the 
mass of the remaining white blood cells, 1 ml 
of cold distilled water (autoclaved), and then 
the contents of the tube were transferred to a 
1.5 ml microtube. The tubes were centrifuged 
for 1 minute at about 5,000 rpm. The 
supernatant was discarded and added to each 
600λ tris buffer and mixed. Then, 100λSDS10% 
and 50λ proteinase K (1 mg/ml) was added to 
each tube and after mixing the microtubes and 
place the shaker at 55 °C for one overnight. 
The samples were digested to one third of their 
volume of saturated saline solution (NaCl 5 M) 
and, after gentle mixing, were centrifuged at 
12000 rpm at a cold temperature for 10 
minutes. The supernatant was transferred to 
another microtube and added to the same 
volume of isopropanol alcohol stored at -20 °C, 
and then the microtube was shaken to appear 
DNA strands and then centrifuged at 12000 
rpm at a cold temperature for 2 minutes. The 
supernatant was discarded and the DNA was 
washed three times with 75% ethanol and each 
time the microtube was centrifuged at 12000 
rpm and the cold temperature for 2 minutes. 
At the last step, after removing the 
supernatant, the microtubes were returned to 
the drying paper and allowed to completely 
dry the DNA. To each microtube, 100 λ 
distilled water was added to the autoclave, 
allowing DNA to be completely dissolved and 
a uniform solution was obtained. The DNA 
extraction was determined on agarose gel 1% 
and then the isolated DNA was placed in 
separate microtubes and stored at -20 °C. 
PCR-RFLP: Determination of genotypes was 
carried out by the PCR-RFLP method by the 
China3 and China4 primers (Table 1), which 
are part of the exon 3 and intron 2 beta-globin 
gene (Figure 1). PCR was performed in final 
volume of 20 μl using Sinagene PCR kit. The 
termocycler program is presented in table 2. To 
assay the correct replication, the PCR products 
were loaded on agarose gel 1.5% and quality of 
the bands was determined.  
 
 
Figure 1. Enzymatic digestion of PCR products 
by Ssp1, the Polymerase chain reaction  
(PCR)-proliferated pieces are 216 bp and 206bp 
without cutting. In the presence of the 
restriction enzyme with cut positions, it  
results in three pieces 200, 16, and 206 bp. 
 
Table 1. Specifications and sequencing of China3 and China4 primers 
DNA Oligo Name Oligo ID. Sequence GC% NO, Bases Tm 
China3 161026J2Go11/2 GTGTACACATATTGACCAAA 35 20 45.6 
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Table 2. Polymerase chain reaction (PCR) proliferation conditions 
Gene Cycling condition 
beta-globin Initial denaturation Denaturation Annealing Extension Final extension 
 C°95 10 Minutes C°95 60 Seconds C°55 45 Seconds C°72 60 Seconds C°72 7 min 
Repeated for 38 cycles 
 
In order to cut the position, the SspI enzyme 
was selected, which is detected as ATT^AAT. 
If this sequence and cut is present, it was 
marked with + and in case of lack of it and 
conversion of special sequence to SspI to  
GTT AAT sequence due to mutation in 
nucleotide 666, it is shown with-sign. The  
PCR-proliferated pieces are 216 bp and 206bp 
without cutting. If the restriction enzyme had 
cut positions, it would result in three pieces of 
200, 16, and 206 bp. Then the PCR products 
were affected by 10 units of SspI enzyme at  
37 °C at one overnight and then the digested 
products were loaded on 3% agarose gel and 
their genotypes were determined (Figure 1).  
Statistical Analysis: Data analysis was 
performed using software POPGENE1.32 and 
SPSS (version 20, IBM Corporation, Armonk, 
NY, USA) at the significance level of P < 0.05. 
Results 
This study was performed on 200 individuals, 
including 100 cases with thalassemia-trait and 
100 healthy controls. Figure 1 shows the image 
of the agarose gel 3%, the polymorphic 
position, and also how to determine its 
genotype compared to ladder and size pieces 
as described above. 
The analysis of results show that of the  
200 individuals or 400 chromosomes 
examined, 166 individuals (78 and 88% in cases 
and controls, respectively) were positive (+) 
for SspI position and 34 individuals (22 and 
12% in cases and controls, respectively) were 
negative (-) (Table 3 and Figure 2).  
 
Table 3. Frequency of + and - SspI sites in  
beta thalassemia and healthy controls 
Groups N )%( Locus 
Beta thalassemia carrier 78 (78) + 
Beta thalassemia carrier 11 (22) - 
Healthy 88 (88) + 
Healthy 12 (12) - 
 
Besides, statistical analysis was performed 
by logistic regression for these sites between 
the carrier and healthy groups and there was 
no significant relationship between these two 
groups in SspI position in beta-globin gene 
(Table 4) (OR = 0.483, P = 0.189).  
 
 
Figure 2. Frequency of position + and – SspI 
position in subjects studied 
Discussion 
More than 95% of the total β-thalassemia 
mutations in the world are spot mutations in 
the β-globin gene and a small percentage of 
other mutations. The studies carried out in the 
last two decades in different provinces of the 
country indicate the dispersion of mutations in 
terms of type and frequency, due to genetic-
ethnic heterogeneity.3  
Table 4. Logistics regression output for data analysis 
Variables in the Equation B S.E. Wald df Sig. Exp (B) 95% CI for EXP (B) 
Lower Upper 
Step 1a RFLP -0.727 0.553 1.726 1 0.189 0.483 0.164 1.430 
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More than 200 different mutations known 
for beta gene have been reported in over  
60 Iranian patients. Several mutations that are 
responsible for β-thalassemia in Iran are of 
Iranian, Mediterranean, Kurdish, Turkish, 
Egyptian, Tunisian, Asian-Indian, Indian, and 
African-American backgrounds. Some 
mutations such as IVSII-1 (G-A) appear in 
most tribes, while others, such as Codon36/37 
(-T), are particularly specific in Lorestan 
province.4 The codon 8/8 (+ G) mutation has 
been introduced among the Kurdish 
population in Kurdistan province and West 
Azerbaijan in terms of common mutations.4 
According to a recent report issued by the 
United Nations over the past two decades, Iran 
has hosted many people who have often 
arrived from Iraq and Afghanistan. Iran has a 
high population with a combination of 
different ethnic groups, indicating the 
frequency and distribution of mutations in 
different parts of the country.1-6 
Statistical analysis was performed by 
logistic regression for these sites between the 
carrier and healthy groups and there was no 
significant relationship between these two 
groups at SspI position in the beta-globin gene. 
This study is the first report in Kurdistan 
province. The results showed that the negative 
status in the thalassemia minor was higher 
than that of healthy people. A total of two 
studies have been conducted in this regard, 
one in Iran and another abroad. In a study by 
Braun et al. on African and Mediterranean 
populations, the frequency of polymorphism 
in the SspI position was reported to be 14%.14 
In another study by Akhavan Niaki et al. in 
Mazandaran, 211 thalassemia carriers were 
examined. Of the 422 chromosomes examined, 
20.6% were negative for SspI. Negative sites 
were approximately equal to healthy and 
mutated alleles (11.9 and 14.3%, respectively).12 
In the present study, 22% of the negative SspI 
site was almost near the prevalence of this 
polymorphism in Mazandaran. The 
polymorphic positions in the population 
genetics and population diseases are the most 
informative. Due to the distance of the locus 
from the mutation site and also the elimination 
of the possibility of false results in terms of 
recombination and statistical analysis, the 
frequency above 10% of a polymorphism loci 
is worth examining for traceability of its 
alleles.13-14  
Most of the polymorphic locations of the β-
globin gene cluster are located outside of the β-
globin gene, and as a result, there is a new 
combination probability, with some of them 
being of low frequency.12 Thus, using in-gene 
sites such as Ssp1 with the presence of 
polymorphism in the population is necessary. 
The AvaII polymorphic position in intron II of 
the β-globin gene has previously been 
investigated by researchers in the Iranian 
population.12-13 Regarding the prevalence of 
polymorphism in this loci and the lower cost of 
SspI by half the cost of the AvaII enzyme, the 
polymorphism of the SspI site in intron II of 
the β-globin gene is an appropriate place for 
the genotype to be investigated indirectly 
(RFLP).13-14 Moreover, since the frequency of 
absence of SspI locus in the population of 
Kurdistan province is more than 10% (22%), 
the negative SspI status is a good indication for 
its pursuit. Due to the importance of diagnostic 
accuracy in prenatal diagnostic tests and the 
possibility of human and laboratory errors, it is 
recommended to use two different methods to 
determine fetal genotype. 
Conclusion 
In cases where mutation of the beta-globin 
gene is not detectable, in which the type of 
parent mutation has been identified, the 
polymorphism of the SspI site can be used as a 
complementary method for confirming the 
fetus genotype. 
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